Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody under investigation in phase 3 clinical trial. Engineered with Tetrabody technology, ivonescimab blocks PD-1 binding to PD-L1 and PD-L2, and blocks VEGF binding to VEGF receptors. PD-1 inhibitors combined with VEGF inhibitors have shown robust efficacy in several tumor types, including renal cell carcinoma, NSCLC, and hepatocellular carcinoma. The use of ivonescimab monotherapy to inhibit PD-1 and VEGF co-expression in the tumor microenvironment may block these 2 pathways more effectively and enhance the antitumor activity compared with combination therapy.